Title Center Name Physician

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (KEYLYNK-008)

NCT ID : 03976362
Protocol Number : MK-7339-008
Phase : 3

Clinical Trials

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Mena

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (KEYLYNK-006)

NCT ID : 03976323
Protocol Number : MK-7339-006
Phase : 3

Clinical Trials

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Mena

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

NCT ID : 02033616
Phase : 2

Clinical Trials

Gynecologic Oncology

Friedman

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

NCT ID : 02947347
Phase : 3

Clinical Trials

Hematology Oncology

Mena

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer

NCT ID : 02589938
Phase : 3

Brain Tumors & Neuroscience

Clinical Trials

Mena

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma

NCT ID : 01781468
Phase : 3

Brain Tumors & Neuroscience

Clinical Trials

Sanghani

A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer (ATALANTE 1)

NCT ID : 02654587

Clinical Trials

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Mena

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

NCT ID : 02954991
Phase : 2

Clinical Trials

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Mena

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NCT ID : 01872975

Breast Surgery and Oncology

Clinical Trials

Sanghani

Palbociclib in Hormone Receptive Positive Advanced Breast Cancer: A Prospective Multicenter Non-International Study (POLARIS)

NCT ID : 03280303

Breast Surgery and Oncology

Clinical Trials

Shankar

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT ID : 03345095
Phase : 3

Brain Tumors & Neuroscience

Kesari

Pemetrexed for the Treatment of Chordoma

NCT ID : 03955042
Phase : 1

Brain Tumors & Neuroscience

Kesari

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

NCT ID : 03688204

Breast Surgery and Oncology

Gordon and Grumley

Integrating Family Caregiver Support into Cancer Clinical Trials

NCT ID : 03069287

Cancer Support

Saria

A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

NCT ID : 03978611
Phase : 1/2a

Melanoma, Skin and Soft Tissue Tumors

O'Day

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)

NCT ID : 03924895
Phase : 3

Urology and Urologic Oncology

Twardowski

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT ID : 03924856
Phase : 3

Urology and Urologic Oncology

Twardowski

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy

NCT ID : 03898180
Protocol Number : MK-7902-011
Phase : 3

Urology and Urologic Oncology

Twardowski

StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)

NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP

Brain Tumors & Neuroscience

Langevin

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT ID : 03709888
Protocol Number : JWCI-17-0101

Brain Tumors & Neuroscience

Kesari

An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer

NCT ID : 03069105

Cancer Support

Saria

CancerLife: Patient-Driven Solution in Cancer Care

NCT ID : 03371147

Cancer Support

Saria

Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease

NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2

Brain Tumors & Neuroscience

Kesari

Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002

Brain Tumors & Neuroscience

Langevin

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 11

Brain Tumors & Neuroscience

Kesari

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT ID : 03425292
Protocol Number : JWCI-17-0801

Brain Tumors & Neuroscience

Kesari

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)

NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3

Brain Tumors & Neuroscience

Kesari

TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men with DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

NCT ID : NCT03148795
Protocol Number : MDV3800-06 (C3441006)
Phase : 2

Urology and Urologic Oncology

Twardowski

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

NCT ID : NCT03860272
Protocol Number : C-800-01
Phase : 1

Breast Surgery and Oncology

Melanoma, Skin and Soft Tissue Tumors

O'Day

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2

Breast Surgery and Oncology

Melanoma, Skin and Soft Tissue Tumors

O'Day

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

NCT ID : 03637764
Protocol Number : ACT15377
Phase : 1 and 2

Brain Tumors & Neuroscience

Kesari

Open- Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer

NCT ID : 03686683
Protocol Number : P17-1 (ProVent)
Phase : 3

Urology and Urologic Oncology

Twardowski

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2

Melanoma, Skin and Soft Tissue Tumors

O'Day

Using Virtual Reality (VR) Models for Preoperative Planning

NCT ID : 03334344
Protocol Number : VR Models

Urology and Urologic Oncology

Linehan

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I

Brain Tumors & Neuroscience

Kesari

A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day

Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II

Brain Tumors & Neuroscience

Kesari

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II

Urology and Urologic Oncology

Twardowski

The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence

NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2

Urology and Urologic Oncology

Linehan

A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)

NCT ID : 03131960
Protocol Number : MT-St-03
Phase : 3

Brain Tumors & Neuroscience

Langevin

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3

Melanoma, Skin and Soft Tissue Tumors

O'Day

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2

Brain Tumors & Neuroscience

Kesari

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Urology and Urologic Oncology

Twardowski

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : IIB or IIIA

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

O'Day

A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas

NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II

Brain Tumors & Neuroscience

Kesari

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy

NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II

Urology and Urologic Oncology

Wilson

A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I

Brain Tumors & Neuroscience

Kesari

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II

Brain Tumors & Neuroscience

Kesari

Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD

NCT ID : 02285101
Protocol Number : BCT-100-005
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day